Research ExplorerPublicationsThe influence of atrial high-rate episodes on stroke and car...

The influence of atrial high-rate episodes on stroke and cardiovascular death: an update

Standard

The influence of atrial high-rate episodes on stroke and cardiovascular death: an update. / Tönnis, Tobias; Bertaglia, Emanuele; Brandes, Axel; Dichtl, Wolfgang; Becher, Nina; de Groot, Joris R; Marijon, Eloi; Mont, Lluís; Blomström-Lundqvist, Carina; Cabanelas, Nuno; Dan, G. Andrei; Lubinski, Andrzej; Merkely, Béla; Rajappan, Kim; Sarkozy, Andrea; Velchev, Vasil; Wichterle, Dan; Kirchhof, Paulus.

In: EUROPACE, Vol. 25, No. 7, euad166, 04.07.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tönnis, T, Bertaglia, E, Brandes, A, Dichtl, W, Becher, N, de Groot, JR, Marijon, E, Mont, L, Blomström-Lundqvist, C, Cabanelas, N, Dan, GA, Lubinski, A, Merkely, B, Rajappan, K, Sarkozy, A, Velchev, V, Wichterle, D & Kirchhof, P 2023, 'The influence of atrial high-rate episodes on stroke and cardiovascular death: an update', EUROPACE, vol. 25, no. 7, euad166. https://doi.org/10.1093/europace/euad166

APA

Tönnis, T., Bertaglia, E., Brandes, A., Dichtl, W., Becher, N., de Groot, J. R., Marijon, E., Mont, L., Blomström-Lundqvist, C., Cabanelas, N., Dan, G. A., Lubinski, A., Merkely, B., Rajappan, K., Sarkozy, A., Velchev, V., Wichterle, D., & Kirchhof, P. (2023). The influence of atrial high-rate episodes on stroke and cardiovascular death: an update. EUROPACE, 25(7), [euad166]. https://doi.org/10.1093/europace/euad166

Vancouver

Tönnis T, Bertaglia E, Brandes A, Dichtl W, Becher N, de Groot JR et al. The influence of atrial high-rate episodes on stroke and cardiovascular death: an update. EUROPACE. 2023 Jul 4;25(7). euad166. https://doi.org/10.1093/europace/euad166

Bibtex

@article{5e882e308fac4cf48100aff3f95c282a,
title = "The influence of atrial high-rate episodes on stroke and cardiovascular death: an update",
abstract = "Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate episodes occur in 10-30% of elderly patients without atrial fibrillation. However, it remains unclear whether the presence of these arrhythmias has therapeutic consequences. The presence of AHRE increases the risk of stroke compared with patients without AHRE. Oral anticoagulation would have the potential to reduce the risk of stroke in patients with AHRE but is also associated with a rate of major bleeding of ∼2%/year. The stroke rate in patients with AHRE appears to be lower than the stroke rate in patients with atrial fibrillation. Wearables like smart-watches will increase the absolute number of patients in whom atrial arrhythmias are detected. It remains unclear whether anticoagulation is effective and, equally important, safe in patients with AHRE. Two randomized clinical trials, NOAH-AFNET6 and ARTESiA, are expected to report soon. They will provide much-needed information on the efficacy and safety of oral anticoagulation in patients with AHRE.",
keywords = "Aged, Anticoagulants/therapeutic use, Atrial Fibrillation/complications, Heart Atria, Humans, Risk Factors, Stroke/diagnosis",
author = "Tobias T{\"o}nnis and Emanuele Bertaglia and Axel Brandes and Wolfgang Dichtl and Nina Becher and {de Groot}, {Joris R} and Eloi Marijon and Llu{\'i}s Mont and Carina Blomstr{\"o}m-Lundqvist and Nuno Cabanelas and Dan, {G. Andrei} and Andrzej Lubinski and B{\'e}la Merkely and Kim Rajappan and Andrea Sarkozy and Vasil Velchev and Dan Wichterle and Paulus Kirchhof",
year = "2023",
month = jul,
day = "4",
doi = "10.1093/europace/euad166",
language = "English",
volume = "25",
journal = "EUROPACE",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - The influence of atrial high-rate episodes on stroke and cardiovascular death: an update

AU - Tönnis, Tobias

AU - Bertaglia, Emanuele

AU - Brandes, Axel

AU - Dichtl, Wolfgang

AU - Becher, Nina

AU - de Groot, Joris R

AU - Marijon, Eloi

AU - Mont, Lluís

AU - Blomström-Lundqvist, Carina

AU - Cabanelas, Nuno

AU - Dan, G. Andrei

AU - Lubinski, Andrzej

AU - Merkely, Béla

AU - Rajappan, Kim

AU - Sarkozy, Andrea

AU - Velchev, Vasil

AU - Wichterle, Dan

AU - Kirchhof, Paulus

PY - 2023/7/4

Y1 - 2023/7/4

N2 - Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate episodes occur in 10-30% of elderly patients without atrial fibrillation. However, it remains unclear whether the presence of these arrhythmias has therapeutic consequences. The presence of AHRE increases the risk of stroke compared with patients without AHRE. Oral anticoagulation would have the potential to reduce the risk of stroke in patients with AHRE but is also associated with a rate of major bleeding of ∼2%/year. The stroke rate in patients with AHRE appears to be lower than the stroke rate in patients with atrial fibrillation. Wearables like smart-watches will increase the absolute number of patients in whom atrial arrhythmias are detected. It remains unclear whether anticoagulation is effective and, equally important, safe in patients with AHRE. Two randomized clinical trials, NOAH-AFNET6 and ARTESiA, are expected to report soon. They will provide much-needed information on the efficacy and safety of oral anticoagulation in patients with AHRE.

AB - Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate episodes occur in 10-30% of elderly patients without atrial fibrillation. However, it remains unclear whether the presence of these arrhythmias has therapeutic consequences. The presence of AHRE increases the risk of stroke compared with patients without AHRE. Oral anticoagulation would have the potential to reduce the risk of stroke in patients with AHRE but is also associated with a rate of major bleeding of ∼2%/year. The stroke rate in patients with AHRE appears to be lower than the stroke rate in patients with atrial fibrillation. Wearables like smart-watches will increase the absolute number of patients in whom atrial arrhythmias are detected. It remains unclear whether anticoagulation is effective and, equally important, safe in patients with AHRE. Two randomized clinical trials, NOAH-AFNET6 and ARTESiA, are expected to report soon. They will provide much-needed information on the efficacy and safety of oral anticoagulation in patients with AHRE.

KW - Aged

KW - Anticoagulants/therapeutic use

KW - Atrial Fibrillation/complications

KW - Heart Atria

KW - Humans

KW - Risk Factors

KW - Stroke/diagnosis

U2 - 10.1093/europace/euad166

DO - 10.1093/europace/euad166

M3 - SCORING: Journal article

C2 - 37345804

VL - 25

JO - EUROPACE

JF - EUROPACE

SN - 1099-5129

IS - 7

M1 - euad166

ER -